ChabioTech Confirms Tolerability and Safety of 'CBT101' Phase 1 Clinical Trial in Solid Tumor Patients
[Asia Economy Reporter Minji Lee] Cha Biotech announced on the 3rd that in a Phase 1 clinical trial evaluating the tolerability and safety of 'CBT101' in solid cancer patients who completed adjuvant therapy after radical resection, no subjects in the tolerability evaluation group experienced 'dose-limiting toxicity (DLT)', and no adverse reactions related to the investigational drug were observed.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
